<DOC>
	<DOCNO>NCT01594502</DOCNO>
	<brief_summary>The goal study apply cutting-edge imaging approach , incorporate machine-learning pattern recognition multispectral analysis , development validation intermediate endpoint biomarkers benign tissue characterize response 5α-reductase inhibitor chemoprevention well risk prostate cancer among men negative biopsy .</brief_summary>
	<brief_title>Validation Digital Morphometry Cancer Risk Benign Prostate Biopsies</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>complete REDUCE trial ( Year 4 exit biopsy block HE slide available ; i.e. , U.S. participant ) compliant assign treatment base either : ( dutasteride group ) least 3 postbaseline serum DHT level ≥ 50 % low baseline , ( placebo group ) least 3 postbaseline serum DHT level none show ≥ 50 % decrease baseline</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>dutasteride</keyword>
</DOC>